Pharsight

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122	NOVO	Acylated GLP-1 compounds	Mar, 2026 (3 years from now)
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (9 years from now)
CN101133082A	NOVO	Acylated Glp-1 Compound	Mar, 2026 (3 years from now)
CN101133082B	NOVO	Acylated Glp-1 Compounds	Mar, 2026 (3 years from now)
IN262697B	NOVO	Acylated Glp-1 Analogs Comprising Non-Proteogenic Amino Acid Residue	Mar, 2026 (3 years from now)
IN200705107P1	NOVO	Acylated Glp-1 Compounds	Mar, 2026 (3 years from now)
EP2322546B1	NOVO	Acylated Glp-1 Compounds	Mar, 2026 (3 years from now)
EP2322546A1	NOVO	Acylated Glp-1 Compounds	Mar, 2026 (3 years from now)
EP1863839B1	NOVO	Acylated Glp-1 Compounds	Mar, 2026 (3 years from now)
EP1863839A2	NOVO	Acylated Glp-1 Compounds	Mar, 2026 (3 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003	NOVO	Use of long-acting GLP-1 peptides	Jun, 2033 (10 years from now)
US10888605	NOVO	GLP-1 compositions and uses thereof	Aug, 2038 (15 years from now)

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

Drug name - Wegovy